Age-specific prevalence of diagnosed systemic lupus erythematosus in Germany 2002 and projection to 2030

Lupus ◽  
2014 ◽  
Vol 23 (13) ◽  
pp. 1407-1411 ◽  
Author(s):  
R Brinks ◽  
R Fischer-Betz ◽  
O Sander ◽  
J G Richter ◽  
G Chehab ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Health Insurance ◽  
Lupus Erythematosus ◽  
Case Definition ◽  
German Population ◽  
Systemic Lupus ◽  
Health Insurance Data ◽  
Gender And Age ◽  
Insurance Data ◽  
Future Population

Objective The objective of this report is to estimate the prevalence and future number of cases of systemic lupus erythematosus (SLE) in Germany. Methods Data from a representative sample of all insurants from the statutory health insurance in Germany comprising more than 2.3 million individuals have been screened for SLE diagnoses. The gender- and age-specific prevalence of SLE is calculated. The case definition is based on at least one recorded diagnosis of SLE during 2002. The stratum-specific prevalence is applied to the current and the future population of Germany in order to estimate and predict the number of people with SLE until 2030. Results The overall prevalence of diagnosed SLE in 2002 was 15.4 (95% CI: 13.1–17.9) and 55.4 (51.4, 59.8) per 100,000 in the male and female German population. This corresponds to an estimated 30,000 and 31,000 people with diagnosed SLE in 2002 and 2010, respectively. This number will slightly increase until 2020 and decrease thereafter. Conclusions Compared with health insurance data from France, the prevalence in our data is similar. Under the assumption that the gender- and age-specific prevalence of SLE in Germany will not change considerably, the number of cases in the next two decades will change only slightly.

scholarly journals Increasing prevalence of Addison's disease in German females: health insurance data 2008–2012

2014 ◽  
Vol 170 (3) ◽  
pp. 367-373 ◽  
Author(s):  
Gesine Meyer ◽  
Kathrin Neumann ◽  
Klaus Badenhoop ◽  
Roland Linder
Keyword(s):  
Health Insurance ◽  
Routine Data ◽  
Addison’S Disease ◽  
Epidemiological Studies ◽  
Steady Increase ◽  
Addison's Disease ◽  
German Population ◽  
Health Insurance Data ◽  
Pronounced Increase ◽  
Insurance Data

ObjectiveOur objective was to investigate the epidemiology of autoimmune Addison's disease (AD) in Germany.DesignRoutine data were analyzed from the Statutory Health Insurance (SHI) database of the Techniker Krankenkasse (TK) for an observation period from 01/01/2008 to 31/12/2012. The TK is one of the largest German health care insurance providers covering more than 10% of the German population.Subjects and methodsBetween 2008 and 2012, a total of 2477 diagnoses of primary adrenal failure were recorded in the SHI database. After exclusion of secondary, iatrogenic or other non-idiopathic forms and after adjustment for incomplete data sets, 1364 diagnoses of autoimmune-mediated AD remained.ResultsThe prevalence of AD in our cohort showed a steady increase from 82 per million in 2008 to 87 per million in 2012. On average, the prevalence rose about 1.8% per year, and due to a pronounced increase (2.7%) in females. The prevalence was lower in men (63–68 per million) than in women (96–108 per million). Autoimmune comorbidities were found in 46.5% of AD patients. Adrenal crises were documented with a frequency of 14–17/100 patient years.ConclusionsThese data provide a first epidemiological profile of this rare and perilous endocrine disease in Germany. Although the prevalence of AD appears lower than in the Scandinavian countries, the increasing figures in females over the last 5 years warrant further investigations. Furthermore, adrenal crises pose a considerable burden. Hereby, we can show that health insurance data provide a valuable tool for epidemiological studies in the absence of national registries.

Systemic Lupus Erythematosus: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data

Vaccine ◽  
2016 ◽  
Vol 34 (51) ◽  
pp. 6572-6581 ◽  
Author(s):  
Aimee O. Hersh ◽  
Graciela S. Alarcón ◽  
Caterina Bonetto ◽  
Yolanda Brauchli Pernus ◽  
Merita Kucuku ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Data Collection ◽  
Lupus Erythematosus ◽  
Safety Data ◽  
Case Definition ◽  
Systemic Lupus ◽  
Systemic Lupus Erythematosus Case

scholarly journals Incorporating Unstructured Patient Narratives and Health Insurance Claims Data in Pharmacovigilance: Natural Language Processing Analysis of Patient-Generated Texts About Systemic Lupus Erythematosus

10.2196/29238 ◽  
2021 ◽  
Vol 7 (6) ◽  
pp. e29238
Author(s):  
Shinichi Matsuda ◽  
Takumi Ohtomo ◽  
Shiho Tomizawa ◽  
Yuki Miyano ◽  
Miwako Mogi ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Health Insurance ◽  
Language Processing ◽  
Lupus Erythematosus ◽  
Insurance Claims ◽  
Systemic Lupus ◽  
Patient Level ◽  
Insurance Claims Data ◽  
Health Insurance Claims Data ◽  
Health Insurance Claims

Background Gaining insights that cannot be obtained from health care databases from patients has become an important topic in pharmacovigilance. Objective Our objective was to demonstrate a use case, in which patient-generated data were incorporated in pharmacovigilance, to understand the epidemiology and burden of illness in Japanese patients with systemic lupus erythematosus. Methods We used data on systemic lupus erythematosus, an autoimmune disease that substantially impairs quality of life, from 2 independent data sets. To understand the disease’s epidemiology, we analyzed a Japanese health insurance claims database. To understand the disease’s burden, we analyzed text data collected from Japanese disease blogs (tōbyōki) written by patients with systemic lupus erythematosus. Natural language processing was applied to these texts to identify frequent patient-level complaints, and term frequency–inverse document frequency was used to explore patient burden during treatment. We explored health-related quality of life based on patient descriptions. Results We analyzed data from 4694 and 635 patients with systemic lupus erythematosus in the health insurance claims database and tōbyōki blogs, respectively. Based on health insurance claims data, the prevalence of systemic lupus erythematosus is 107.70 per 100,000 persons. Tōbyōki text data analysis showed that pain-related words (eg, pain, severe pain, arthralgia) became more important after starting treatment. We also found an increase in patients’ references to mobility and self-care over time, which indicated increased attention to physical disability due to disease progression. Conclusions A classical medical database represents only a part of a patient's entire treatment experience, and analysis using solely such a database cannot represent patient-level symptoms or patient concerns about treatments. This study showed that analysis of tōbyōki blogs can provide added information on patient-level details, advancing patient-centric pharmacovigilance.

Medication adherence of patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis Considering the Psychosocial Factors, Health Literacy and Current Life Concerns of Patients

2021 ◽  
Vol 17 ◽  
Author(s):  
Saeedeh Shenavandeh ◽  
Arash Mani ◽  
Mehdi Eazadnegahdar ◽  
Ali Nekooeian
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Prognostic Factors ◽  
Health Insurance ◽  
Medication Adherence ◽  
Health Literacy ◽  
Psychosocial Factors ◽  
Lupus Erythematosus ◽  
Drug Exposure ◽  
Systemic Lupus

Background: In systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), due to their long term, multi-drug exposure and their side effects, non-adherence to therapy is common and is associated with adverse clinical outcome. In this study, we aimed to evaluate and compare medication adherence in patients with SLE and RA considering their psychosocial factors, health literacy, and current life concerns. Methods: 88 patients fulfilled the criteria of RA(N:46) and SLE(N:42);using disease-modifying antirheumatic drugs or immunosuppressive, we evaluated, their demographic data, co-morbid diseases, the number of medications, estimated income, having health insurance, family size and disease poor prognostic factors. The 8-item Morisky’s Medication Adherence, Depression by Beck depression inventory (21 Q), and drug literacy level were used. Results: Medication non-adherence was seen in 91.3% of the RA group and 90.4% of the SLE group. Moderate to very severe depression was seen in [21 (45.7%)] and [12 (25.9%)] of the RA and SLE patients, respectively. In the SLE group, depression and having poor prognostic factors, and in the RA group, depression, having co-morbid diseases and higher pill numbershad a significant effect on medication adherence. Conclusion: There was a high prevalence of drug non-adherence in our RA and SLE patients. The most prevalent factor in non-adherence in both groups was depression. After that, in RA patients the presence of co-morbid disease and in SLE patients the presence of poor prognostic factors were related to non-adherence. Factors like income, health insurance, disease duration, and health literacy had no significant effect on medication adherence.

Sign in / Sign up

Export Citation Format

Share Document